Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16–17
HOS-109484 · Präparat HOS-093201
16
Non-steroidal selective mineralocorticoid receptor (MR) antagonists
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0- 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax 114% needed.
Diclofenac AUC0- 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax 1.7-fold other long-acting opiates
Oxycodone AUC0- 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUC 47% reactions and toxicity related to
S-methadone Cmax 65% methadone, including QTc
S-methadone AUC 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0- 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0- 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUC 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax 14%
Voriconazole AUC 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 8ddbb18c489ccc11c6814ac36e2fb24fd816c63d5b15490877a83dbf46e7d7f5 · Zeichen 27474–31780 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 48–49
HOS-109554 · Präparat HOS-093201
48
Non-steroidal selective mineralocorticoid receptor (MR) antagonists
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0- 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax 114% needed.
Diclofenac AUC0- 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax 1.7-fold other long-acting opiates
Oxycodone AUC0- 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUC 47% reactions and toxicity related to
S-methadone Cmax 65% methadone, including QTc
S-methadone AUC 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0- 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0- 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUC 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax 14%
Voriconazole AUC 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage e6233d476ccce7daca52d1dd2aaaa91e8c3161bd371e92e18ca8a2257625f3c2 · Zeichen 27978–32284 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 80–81
HOS-109619 · Präparat HOS-093201
80
Non-steroidal selective mineralocorticoid receptor (MR) antagonists
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0- 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax 114% needed.
Diclofenac AUC0- 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax 1.7-fold other long-acting opiates
Oxycodone AUC0- 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUC 47% reactions and toxicity related to
S-methadone Cmax 65% methadone, including QTc
S-methadone AUC 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0- 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0- 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUC 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax 14%
Voriconazole AUC 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 5c1a7a3fda98976f51693be4906d67df598ab85a4fcf5f8cd51e8c0fe387196a · Zeichen 27504–31810 im Abschnitt
Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)
Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 17–18
HOS-130968 · Präparat HOS-096981
17
Finerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
finerenone.
Eplerenone Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
eplerenone.
Non-steroidal anti-inflammatory drugs (NSAIDs)
[CYP2C9 substrates] Frequent monitoring for adverse
S-Ibuprofen Cmax ↑ 20% reactions and toxicity related to
Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-∞ ↑ 100% NSAIDs is recommended. Dose
reduction of NSAIDs may be
Diclofenac (50 mg single dose) Diclofenac Cmax ↑ 114% needed.
Diclofenac AUC0-∞ ↑ 78%
Opioids
Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and
[CYP3A4 substrates] Oxycodone Cmax ↑ 1.7-fold other long-acting opiates
Oxycodone AUC0-∞ ↑ 3.6-fold metabolised by CYP3A4
Oxycodone (10 mg single (e.g., hydrocodone) should be
dose) considered. Frequent monitoring
for opiate-associated adverse
reactions may be necessary.
Methadone (32-100 mg QD) R-methadone (active) Cmax ↑ 31% Frequent monitoring for adverse
[CYP3A4 substrate] R-methadone (active) AUCτ ↑ 47% reactions and toxicity related to
S-methadone Cmax ↑ 65% methadone, including QTc
S-methadone AUCτ ↑ 103% prolongation, is recommended.
Dose reduction of methadone
may be needed.
Short-acting Opiates Dose reduction of alfentanil,
[CYP3A4 substrates] fentanyl and other short-acting
opiates similar in structure to
Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by
dose, with concomitant Alfentanil AUC0-∞ ↑ 6-fold CYP3A4 (e.g., sufentanil) should
naloxone) be considered. Extended and
frequent monitoring for
Fentanyl (5 µg/kg single dose) In an independent published study, respiratory depression and other
Fentanyl AUC0-∞ ↑ 1.34-fold opiate-associated adverse
reactions is recommended.
Opioid receptor antagonists
Naloxegol Although not studied, voriconazole Contraindicated (see section
[CYP3A4 substrate] is likely to significantly increase 4.3)
the plasma concentrations of
naloxegol.
Oral contraceptives
Oral Contraceptives* Ethinylestradiol Cmax ↑ 36% Monitoring for adverse reactions
[CYP3A4 substrate; CYP2C19 Ethinylestradiol AUCτ ↑ 61% related to oral contraceptives, in
inhibitor] Norethisterone Cmax ↑ 15% addition to those for
Norethisterone/ethinylestradiol Norethisterone AUCτ ↑ 53% voriconazole, is recommended.
(1 mg/0.035 mg QD) Voriconazole Cmax ↑ 14%
Voriconazole AUCτ ↑ 46%
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-23T14:40:00Z · SHA-256 8f5a567ef9a1f0f0bee27abd2100fc7726dcc5281b72b1f33957fd6bcec22b38 · Passage c15a75c62801770f9555f6206fed29c8569fb1a5f9063364f5ddb780efc68271 · Zeichen 27899–32111 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.